Most medicines are manufactured in the same form for every patient. Intismeran is designed differently.
Researchers analyze mutations in an individual patient's tumor and use that information to create an mRNA treatment intended to train the immune system to recognize that person's cancer.
Moderna and Merck are testing intismeran alongside Keytruda, an established immunotherapy, in people with high-risk stage IIB through IV melanoma whose tumors had been completely removed by surgery.
The Phase 3 INTerpath-001 study enrolled 1,137 patients. Participants received either Keytruda with the personalized mRNA treatment or Keytruda alone.
According to the companies' interim announcement, the combination met the trial's primary endpoint of recurrence-free survival and a key secondary endpoint measuring survival without distant metastasis. They also reported no new safety signals.
That moves the approach beyond an encouraging smaller trial and through its first successful large, late-stage test in melanoma.
But the most important numbers have not yet been presented publicly. The companies have not disclosed the Phase 3 effect size, detailed safety findings or overall-survival results.
The trial is also still ongoing, and regulators have not decided whether the evidence supports approval.
This is therefore progress at a clearly defined stage: a personalized mRNA cancer treatment has cleared a major clinical hurdle, while the fuller evidence and regulatory judgment still lie ahead.